Pumps are used in the biopharmaceutical industry for the transfer of fluids such as buffer & media through the tubing & deliver them to process equipment. The single-use pump is a disposable pump & a vital component of the single-use technology sector. These single-use pump chambers eliminate traditional cleaning expenses & enable fast changeovers during the production process. Therefore, on account of increasing flexibility & reduction in batch timings, the single-use pumps would experience a flourishing growth in the coming years.
The Global Single-use Pumps in the Biopharmaceutical market is projected to grow at a CAGR of around 6.21% during the forecast period, 2022-2027. The market experienced a flourishing growth during the historical period, owing to increasing biopharma product manufacturing & other advantages associated with the single-use systems, such as flexibility, scalability, etc., in various developed & emerging economies. The majority of biopharmaceutical processes use single-use technologies, including mammalian cell culture, both upstream & downstream.
Moreover, the rising adoption of single-use systems for producing various modalities such as conventional vaccines, monoclonal antibodies, and mRNA-based vaccines in developing nations ultimately drove the demand for single-use pumps across the globe. According to the International AIDS Vaccine Initiative (IAVI), in 2019, there were eight operational monoclonal antibody manufacturing facilities in Argentina, Brazil, China, India, Japan, and Singapore, while five facilities are under construction in these regions.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: The US, Canada, Mexico|
|South America: Brazil, Argentina, Rest of South America|
|Europe: Germany, The UK, France, Russia Rest of Europe|
|Asia-Pacific: China, India, Japan, South Korea, Rest of Asia-Pacific|
|Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA|
|Key Companies Profiled||PSG Dover, Quantex Arc, Watson Marlow, Colly Flowtech AB, Levitronix, Pumpcell, Fluid Flow, PROMECON GmbH, CerCell, ALMATECHNIK AG, Verder International B.V., ProMinent GmbH, Others|
|Unit Denominations||USD Million/Billion|
Further, single-use pumps are expected to have a prominent demand during the forecast period on account of rising acceptance of single-use systems in biopharma facilities & growing biopharma contract development & manufacturing organizations. Furthermore, biopharma companies have shifted their interest toward contract manufacturing & development facilities, which would present a positive growth outlook for single-use systems during 2022-27.
Key Trend in the Market
The demand for the mRNA-based vaccines was boosted during the COVID-19 pandemic, owing to the successful manufacturing of the mRNA-based Moderna & Pfizer BioNTech vaccines, which provide approximately 94% effectiveness to fully vaccinated adults. Further, these vaccines are easier & quicker to produce than traditional vaccines & are manufactured using readily available raw materials. Additionally, the high effectiveness of mRNA-based vaccines against coronavirus has further accelerated researchers' fascination to pursue mRNA platforms for treating infectious diseases.
Moreover, the adoption of single-use pumps would enable mRNA manufacturers to eliminate the risk of contamination & provide several other benefits. Thus, the growing investments & the shift towards mRNA-based vaccines are expected to enhance the demand for single-use pumps during the forecast period.
Impact of Covid-19 on the Global Single-use Pumps in the Biopharmaceutical Market
The outbreak of COVID-19 prompted biopharmaceutical companies to focus on stopping the spread & replication of the virus worldwide. Meanwhile, the biopharmaceutical industry was leading its way in developing & manufacturing vaccines, diagnostics & treatments to combat the widespread of COVID-19. Therefore, rising R&D in the field of therapeutics led to the approval of COVID-19 vaccines manufactured by companies such as Pfizer-BioNTech, Janssen, and Moderna COVID-19 vaccines, as of March 2021. Furthermore, the pandemic resulted in the rapid scaling up of biopharmaceutical production activities, which ultimately led to the increased demand for products such as single-use systems.
Additionally, among all the products required, single-use systems acquired high demand due to benefits associated with them, such as eliminating the risk of cross-contamination, lower manufacturing costs, and increase in production speed & facility. Besides, with the rise in single-use systems, single-use pumps also experienced a substantial increase as it eliminates the cleaning & sterilization cycles in the upstream & downstream processing.